Combipatch

relieves symptoms associated with menopause. Re-evaluate with your doctor every 3 to 6 months about the dose you are taking and whether you still need Combipatch.

Combipatch Overview

Reviewed: September 7, 2012
Updated: 

Combipatch is a prescription medication used after menopause to reduce moderate to severe hot flashes, treat moderate to severe menopausal changes in and around the vagina, and treat certain conditions in women before menopause if their ovaries do not make enough estrogens naturally. Combipatch contains two hormones, estradiol and norethindrone, and belongs to a group of drugs called estrogen and progestin combinations. Combipatch works as a hormone replacement to relieve issues caused by hormonal changes. 

Combipatch comes in a patch form and is usually applied 2 times each week or every 3 to 4 days.

Common side effects of Combipatch include headache, breast pain, and irregular vaginal bleeding or spotting. 

Patient Ratings for Combipatch

How was your experience with Combipatch?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Combipatch?

What are you taking Combipatch for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Combipatch work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Combipatch to a friend?

Manufacturer

Estradiol and Norethindrone

For more information on this medication choose from the list of selections below.

Combipatch Drug Class

Combipatch is part of the drug class:

Combipatch FDA Warning

Warning: Cardiovascular disorders, breast cancer, endometrial cancer and probable dementia

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.

The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Breast Cancer

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia.

The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone relative to placebo.

The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.